Distinct biomarker of continuous transcutaneous vagus nerve stimulation treatment in major depressive disorder

Article in Brain Stimulation - January 2018
DOI: 10.1016/j.brs.2018.01.006

13 authors, including:

Yiheng Tu
Harvard Medical School
31 PUBLICATIONS  82 CITATIONS

Zengjian Wang
South China Normal University
31 PUBLICATIONS  100 CITATIONS

Jun Liu
China Academy of Chinese Medical Sciences
20 PUBLICATIONS  228 CITATIONS

Bing Zhu
135 PUBLICATIONS  1,265 CITATIONS

Some of the authors of this publication are also working on these related projects:

- Natural Scientific Foundation of China View project
- Autism fmri functional connectivity View project
A distinct biomarker of continuous transcutaneous vagus nerve stimulation treatment in major depressive disorder

Yiheng Tu a,1, Jiliang Fang b,1, Jin Cao a,4, Zengjian Wang a, Joel Park a, Kristen Jorgensen a, Courtney Lang a, Jun Liu b, Guolei Zhang b, Yanping Zhao b, Bing Zhu c, Peijing Rong c,**, Jian Kong a,***

a Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA
b Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
c School of Acupuncture Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China

**Corresponding author. Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China.
***Corresponding author. Psychiatry Department, Massachusetts General Hospital, Harvard Medical School, Building 120, 2nd Ave, Suite 101C, Charlestown, MA 02129, USA.

E-mail addresses: drrongpj@163.com (P. Rong), kongji@nmr.mgh.harvard.edu (J. Kong).

1 Tu and Fang are co-first authors.

Abstract

Background: Major depression is the fourth leading cause of disability worldwide and poses a socioeconomic burden worldwide. Transcutaneous vagus nerve stimulation (tVNS) is a promising noninvasive clinical device that may reduce the severity of major depression. However, the neural mechanism underlying continuous tVNS has not yet been elucidated.

Objective: We aimed to explore the effect of hypothalamic subregion functional connectivity (FC) changes during continuous tVNS treatment on major depressive disorder (MDD) patients and to identify the potential biomarkers for treatment outcomes.

Methods: Forty-one mild to moderate MDD patients were recruited and received either real or sham tVNS treatment for 4 weeks. We used a seed-to-whole brain approach to estimate the FC changes of hypothalamic subregions and their surrounding control areas during continuous tVNS treatment and explored their association with clinical outcome changes after 4 weeks of treatment.

Results: Of the thirty-six patients that completed the study, those in the tVNS group had significantly lower scores on the 24-item Hamilton Depression (HAM-D) Rating Scale compared to the sham tVNS group after 4 weeks of treatment. The FC between the bilateral medial hypothalamus (MH) and rostral anterior cingulate cortex (rACC) was significantly decreased during tVNS but not during sham tVNS. The strength of this FC was significantly correlated with HAM-D improvements after 4 weeks of tVNS.

Conclusion: The FC between the bilateral MH and rACC may serve as a potential biomarker for the tVNS state and predict treatment responses. Our results provide insights into the neural modulation mechanisms of continuous tVNS and reveal a potential therapeutic target for MDD patients.

© 2018 Elsevier Inc. All rights reserved.
Recently, transcutaneous VNS (tVNS), a noninvasive and safe variant of traditional VNS, has drawn the interest of researchers for treating MDD [8–12]. tVNS stimulates the afferent auricular branch of the vagus nerve located on the surface of the ear and produces a similar effect to classical VNS in reducing depressive symptoms without any surgical intervention [11,13]. Although tVNS has shown promising results in treating MDD patients in several studies [8,10,11], its underlying mechanism remains poorly understood.

Using functional magnetic resonance imaging (fMRI), investigators have studied resting-state functional connectivity (rsFC) changes before and after four weeks of treatment [10,14] and fMRI signal changes evoked by intermittent real and sham tVNS using a block design [8,9,15]. Yet, the neural mechanism of tVNS during continuous stimulation, which is the way tVNS is applied in our clinical report [11] and others [13], has rarely been studied. In this manuscript, we propose that continuous electrical stimulation may bring the brain into a new state, known as the “continuous tVNS state” (for abbreviation, we call it the tVNS state in the rest of the paper), offering researchers a new angle to explore the neural modulation and therapeutic effects of tVNS.

The hypothalamus is known to mediate many neuroendocrine and neurovegetative functions [16–18]. Through the hypothalamic-pituitary-adrenal (HPA axis), the hypothalamus drives both the acute cortisol response to stress and cortisol secretion in a circadian rhythm [19–21]. Although the maladaptive activation of the HPA axis is characterized across many studies of depressed patients, other hypothalamic functions and nuclei have remained largely unexplored. A recent study demonstrated decreased hypothalamic functional connectivity (FC) with the subgenual cortex in psychotic major depression, which suggests that hypothalamic communication with the rest of the brain is critically important for many physiological and psychological functions [22]. Therefore, studying how tVNS can modulate the FC of different hypothalamic subregions and its association with clinical improvement can provide us with a better understanding of the mechanism of tVNS and the pathophysiology of depression.

Recently, FC analyses have been widely used to explore the biomarkers for neurologic and psychiatric diseases in order to extend the focus from isolated regions to a network of regions [23–25]. Thus, in the present work, we explored baseline FC differences between the hypothalamus and other brain regions during continuous real and sham tVNS, as well as during the no-stimulation resting state before tVNS stimulation. In addition, we explored the association between FC strength during baseline treatment and clinical improvement after four weeks. We hypothesized that real but not sham tVNS would significantly modulate the FC of the hypothalamus in MDD patients, and this FC may serve as a distinct biomarker for the tVNS state, as well as predict treatment outcomes.

Material and methods

The present study is based on a brain imaging study nested in a clinical trial (ChiCTR-TRC-11001201). The inclusion criteria (e.g., comorbidities, medications) and intervention details (e.g., equipment, MRI environmental setup, electrical stimuli) can be found in the clinical report [26]. In our prior imaging studies, a subset of 35 patients was used to investigate changes in the resting-state default mode network (DMN) after four weeks of tVNS treatment [10], and a subset of 38 patients was used to study the changes in fMRI signals induced by intermittent tVNS [9]. In this study, we focus on how 6 min of continuous tVNS modulates the FC of the hypothalamus, a key region in the limbic system, using a seed-to-whole-brain approach. This continuous tVNS dataset at baseline has never been analyzed or published before.

Participants

The study was approved by the Institutional Ethics Committee of the China Academy of Chinese Medical Sciences. All experiments were performed in accordance with approved guidelines. Due to safety and ethical concerns and to increase the homogeneity of the study, we only included participants with mild or moderate depressive symptoms. All patients were recruited using advertisements and by sending flyers to the hospitals involved in the study. Forty-one patients with mild or moderate MDD were recruited for the trial. ICD-10 classification of mental and behavioral disorders was used for the diagnosis of MDD. Patients who voluntarily provided informed consent and met inclusion criteria were enrolled in this study.

Inclusion criteria: 1) Meets ICD–10 diagnosis standards for a depressive episode: mild (2 typical + 2 other core symptoms), moderate (2 typical + 3 other core symptoms); 2) 18–70 years of age; 3) Willing to stop taking anti-depressive or other psychiatric medications 2 weeks before beginning the intervention; 4) Junior high or higher level education; 5) Exhibit symptoms for 2 weeks to 2 years.

Exclusion criteria: 1) Ongoing addiction to drugs and/or alcohol; 2) Bipolar disorder; 3) Organic mental disorder; 4) Drug-induced depression; 5) Seasonal affective disorder; 6) Severe medical disorders; 7) Pregnant women; 8) Postpartum depression; 9) Dementia or other cognitive disorders; 10) Patients who do not agree to sign the consent form.

Procedures

A single-blinded clinical trial was used to investigate the antidepressant effects of real tVNS treatment. The first cohort of patients all received real tVNS treatment for 12 weeks. After demonstrating the effect of tVNS, we recruited a second cohort of patients who received four weeks of sham tVNS before shifting to real tVNS for eight weeks. At the beginning of the treatment (baseline), the fMRI scans were applied during both resting state and 6-minutes of continuous real or sham tVNS. In this manuscript, we compared FC differences during continuous real tVNS and sham tVNS on the right ear at baseline, as well as predicted treatment outcomes after four weeks (Fig. 1, A).

Intervention

The stimulation points for real tVNS are located in the auricular concha area where there is rich vagus nerve branch distribution (Fig. 1, B). Real tVNS was applied on the concha area of both ears simultaneously during the treatments except during the MRI scan in which tVNS was applied on the right ear. After being disinfected, electrodes were attached to the ear area (i.e. auricular concha) at the stimulation site. Stimulation parameters included: 1) density wave adjusted to 20 Hz with a wave width less than 1 millisecond and 2) intensity adjusted based on the tolerance of the patient (typically between 4 and 6 mA). Each treatment lasted 30 min and was carried out twice a day (i.e. once in the morning and once again in the evening), at least 5 days per week, for the duration of the treatment period (4 weeks). Patients were also instructed to record any side effects of treatment in a diary each day.

The treatment procedure of sham tVNS was the same as real tVNS except that the stimulation points for sham tVNS were located at the superior scapha (outer ear margin midpoint) where there is no vagus nerve distribution [26,27] (Fig. 1, B).
After the baseline MRI scan, all subsequent treatments were self-administered by the patients at home after adequate training. Patients were also instructed to complete a patient diary booklet each day to describe any side effects corresponding with or temporally related to treatment. The investigators checked the patient diaries at the end of the 4-week treatment.

**Clinical outcomes**

The primary clinical outcome measure of this study was the 24-item Hamilton Depression Rating Scale (HAM-D); the secondary outcomes included the 14-item Hamilton Anxiety Rating Scale (HAM-A), the Self-Rating Anxiety Scale (SAS), and the Self-Rating Depression Scale (SDS), which were measured at baseline and week 4.

**Data acquisition**

fMRI data was acquired with a 1.5 T GE Sigma MRI system (GE Healthcare, Buckinghamshire, United Kingdom) equipped with a standard two-channel birdcage head coil. Subjects were asked to stay awake and to keep their heads still during the scan. Prior to the functional run, T1-weighted high-resolution structural images were acquired with the three-dimensional fast spoiled gradient-echo sequence (matrix 192 x 256, field of view 200 mm, flip angle 15°, slice thickness 1.4 mm), T2-weighted functional images encompassing the whole brain were acquired with the gradient echo-planar imaging sequence (echo time 30 ms, repetition time 2500 ms, matrix 64 x 64, field of view 240 mm, flip angle 90°, slice thickness 3.0 mm, gap 0.5 mm, 41 slices, parallel to the anterior commissure-posterior commissure line). Image collection was preceded by four dummy scans to allow for equilibration of the MRI signal.

A 6-minute resting-state fMRI session was acquired prior to treatment. During treatment, the right ear was stimulated continuously for 6 min with either real or sham tVNS. To avoid the noise evoked by the electrical current of the tVNS, the connecting line between the stimulator and the ear was electromagnetically shielded. A round tin electrode, about 5 mm in diameter, was installed at the distant end of the line. The electrodes were fixed by tape during the 6-minute fMRI scan.

**fMRI data analysis**

**fMRI data preprocessing**

The fMRI data were preprocessed and analyzed using SPM12 (Wellcome Trust Center for Neuroimaging, London, UK). The first ten volumes were discarded to allow for signal equilibration. Images were slice timing corrected, head motion corrected, coregistered to respective structural images for each subject, segmented, regressed out 6 head motion parameters, white matter signals, and cerebrospinal fluid (CSF) signals, normalized by using Montreal Neurological Institute (MNI) space [28], and spatially smoothed using a Gaussian kernel of 8 mm full width at half maximum (FWHM = 8 mm). The resulting images were detrended and bandpass filtered (0.01–0.08 Hz). In the last step, global signal regression (GSR) was applied to reduce head motion-related signal changes [29].

**Seed-based FC**

The bilateral medial hypothalamus (MH) (MNI coordinates: $x = \pm 4; y = -2; z = -12$ plus 2 mm sphere) and lateral hypothalamus (LH) (MNI coordinates: $x = \pm 6; y = -9; z = -10$ plus 2 mm sphere) [30] were selected as seeds using WFU-Pick Atlas software [31] (Fig. 1, C). FCs were computed between the time courses of the seed and time courses of every other voxel using Pearson's correlation coefficients. Correlation coefficients were Fisher $z$-transformed to increase normality and allow for statistical analyses. We also selected two null seeds next to the MH ($x = \pm 8; y = -2; z = -12$ plus 2 mm sphere; $x = \pm 4; y = -2; z = -8$ plus 2 mm sphere; Fig. 1, C) and two null seeds next to the LH ($x = \pm 10; y = -9; z = -10$ plus 2 mm sphere; $x = \pm 6; y = -9; z = -6$ plus 2 mm sphere; Fig. 1, C), in order to study the specific phenomenon of the hypothalamus.
Clinical data analyses

All statistical analyses of clinical scores were performed using SPSS 22 (IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.). A two-sample t-test (the normality of the data was tested using a Shapiro-Wilk test) was applied to compare the baseline characteristics between the patients in the real and sham groups. A repeated measurement analysis (the homogeneity of variance was tested using a Levene’s test) was applied to compare the treatment effects (baseline vs. week 4) between the real and sham groups.

Functional data analyses

MH/LH seed-to-voxel FC between-group analyses (continuous real tVNS vs. sham tVNS) were performed using a two-sample t-test. A threshold of a voxel-wise p < 0.01 (uncorrected) and a cluster-level p < 0.05 (cluster-based false discovery rate [FDR] corrected) were applied for the correction of multiple comparisons [32].

To identify the distinct FC biomarkers for the tVNS state and predict treatment effects, we computed partial correlations, adjusting for age and gender, between HAM-D improvements (post-treatment vs. pre-treatment) and extracted FCs from seed-to-voxel between-group analyses. In addition, we also extracted FCs from respective resting-state fMRI scans and correlated them with HAM-D improvements.

Results

Clinical outcome

There were 20 participants in the tVNS group and 21 participants in the sham tVNS group that participated in the baseline MRI scan. Three participants from the tVNS group and one participant from the sham tVNS group were dropped from the study at the end of week four. Baseline characteristics of the two groups are shown in Table 1. No significant differences were observed between the two groups at baseline.

Post-treatment clinical outcomes are also summarized in Table 1. Overall, tVNS treatment (pre vs. post) had significantly lower (real < sham) in the real tVNS group compared to the sham tVNS group. Post-treatment clinical outcomes are also summarized in Table 1. Overall, tVNS treatment (pre vs. post) had significantly lower (real < sham) in the real tVNS group compared to the sham tVNS group.

Functional connectivity results

The strength (represented by z scores) of MH based FCs was significantly lower (real < sham) in the real tVNS group compared to the sham tVNS group in the rostral anterior cingulate cortex (rACC; $p_{\text{cluster-corr}} = 0.023$) and right medial frontal gyrus (MFG; $p_{\text{cluster-corr}} = 0.002$), and significantly higher (real > sham) in the bilateral cerebellum (LCB; $p_{\text{cluster-corr}} = 0.020$ and RCB: $p_{\text{cluster-corr}} = 0.035$; Fig. 2, First column and Table 2). No significant region was observed in the null seeds next to the MH.

Discussion

In the present study, we explored the FC of the subregions of the hypothalamus during real and sham tVNS treatment in MDD patients, as well as the respective resting state FC. We found real tVNS showed significantly higher FC between the MH and cerebellum and lower FC between the MH and both rACC and MFG and decreased FC between the LH and both MCC and putamen compared to sham tVNS. In addition, compared to resting state FC, the FC between the MH and rACC was significantly modulated by real tVNS but not by sham tVNS. The strength of this connection in the tVNS state was significantly correlated with treatment effects after four weeks, suggesting that MH-rACC FC may be a distinct biomarker for the tVNS state and may predict treatment outcomes for depression.

Table 1

<table>
<thead>
<tr>
<th>Clinical Outcome</th>
<th>tVNS Group</th>
<th>Sham tVNS Group</th>
<th>Effect of Treatment</th>
<th>Effect of Interaction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-treatment</td>
<td>Post-treatment</td>
<td>Pre-treatment</td>
<td>Post-treatment</td>
</tr>
<tr>
<td>HAM-D</td>
<td>30.47±4.38</td>
<td>28.90±4.01</td>
<td>23.20±4.53</td>
<td>75.93, $p &lt; 0.001$</td>
</tr>
<tr>
<td>SAS Score</td>
<td>58.53±7.04</td>
<td>58.80±10.38</td>
<td>54.60±6.22</td>
<td>12.54, $p &lt; 0.001$</td>
</tr>
<tr>
<td>SDS Score</td>
<td>70.35±8.23</td>
<td>67.40±8.41</td>
<td>61.15±5.17</td>
<td>23.88, $p &lt; 0.001$</td>
</tr>
</tbody>
</table>

HAM-D: Hamilton Depression Rating Scale; SAS-A: Hamilton Anxiety Rating Scale; SDS: Self-Rating Depression Scale; SDS: Self-Rating Depression Scale.

Please cite this article in press as: Tu Y, et al., A distinct biomarker of continuous transcutaneous vagus nerve stimulation treatment in major depressive disorder, Brain Stimulation (2018). https://doi.org/10.1016/j.brs.2018.01.006
The mechanism of VNS treatment remains unclear. Hypotheses are based on the impact of anatomy and function/neurotransmitter changes evoked by VNS/tVNS in mood control. Studies suggest that the anti-depressant effect of tVNS may be due to the vagal projections from the nucleus tractus solitarius (NTS) to brain structures that are associated with the regulation of mood and emotion [35]. Neuroimaging studies have demonstrated that VNS/tVNS can modulate BOLD responses in widespread brain regions including the hypothalamus, orbitofrontal cortex (OFC), parieto-occipital cortex, temporal lobe, amygdala, insula, thalamus, hippocampus, postcentral gyrus, nucleus accumbens (NAc), and brainstem [15,36–40]. Some of these brain regions are also believed to be involved in the pathogenesis and remission of MDD, particularly the hypothalamus [18,22].

In a previous study, we investigated DMN resting state FC changes at baseline and after four weeks of tVNS and sham tVNS treatment [10]. We found that FC of the DMN within the precuneus and orbital prefrontal cortex increased, and these FC increases were associated with improvements in HAM-D scores. This result reveals how tVNS can modulate intrinsic brain functional connectivity and consequently reduce the severity of major depression. More recently, we studied fMRI signal changes evoked by intermittent real and sham tVNS using a block design to explore potential biomarkers for tVNS longitudinal treatment [9]. We found the activation level in the left anterior insula was enhanced by tVNS compared with sham tVNS, and this enhancement was associated with an improvement in longitudinal treatment outcomes. The identification of a biomarker to characterize the tVNS state could promote our understanding of treatment mechanisms and help in the development of therapeutic targets for MDD.

FC allows researchers to study the pathophysiology of neurologic diseases and to translate fMRI into clinically relevant information. In the present study, we found that (1) the FC between the MH and rACC was significantly modulated by tVNS but not by sham tVNS; and (2) the strength of MH-rACC FC during treatment at baseline was significantly associated with the treatment effect of tVNS.

Table 2
Identified significantly different brain regions between real and sham tVNS groups.

<table>
<thead>
<tr>
<th>Brain Regions</th>
<th>Hemisphere</th>
<th>MNI coordinates</th>
<th>k</th>
<th>T</th>
<th>Z</th>
<th>Peak p (unc)</th>
<th>Cluster p (FDR-corr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham&gt;Real</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rACC</td>
<td>L</td>
<td>-15 41 5</td>
<td>36</td>
<td>4.27</td>
<td>3.81</td>
<td>p &lt; 0.001</td>
<td>p = 0.023</td>
</tr>
<tr>
<td>MFG</td>
<td>R</td>
<td>27 14 44</td>
<td>73</td>
<td>4.73</td>
<td>4.13</td>
<td>p &lt; 0.001</td>
<td>p = 0.002</td>
</tr>
<tr>
<td>Real&gt;Sham</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left CB</td>
<td>L</td>
<td>-33 -55 -13</td>
<td>29</td>
<td>4.09</td>
<td>3.67</td>
<td>p &lt; 0.001</td>
<td>p = 0.020</td>
</tr>
<tr>
<td>Right CB</td>
<td>R</td>
<td>33 -43 -19</td>
<td>46</td>
<td>3.95</td>
<td>3.57</td>
<td>p &lt; 0.001</td>
<td>p = 0.035</td>
</tr>
</tbody>
</table>

Please cite this article in press as: Tu Y, et al., A distinct biomarker of continuous transcutaneous vagus nerve stimulation treatment in major depressive disorder, Brain Stimulation (2018), https://doi.org/10.1016/j.brs.2018.01.006
tVNS in the following four weeks but not the treatment effect of sham tVNS. Therefore, MH-rACC FC could serve as a distinct biomarker for the tVNS state and predict the therapeutic performance of MDD patients after four weeks of tVNS treatment.

Literature suggests that hypothalamic communication with other cortical and subcortical regions of the brain is critical for maintaining neuroendocrine and affective processes [18]. In addition, activity in the anterior cingulate cortex (ACC), particularly the pregenual ACC, has been recognized as a predictor of treatment responses in depression [33]. Mayberg et al. first reported that increased resting glucose metabolism in the rACC before the onset of pharmacological treatment predicted better treatment responses in MDD patients [41]. Similar findings have been reported using EEG [34,42,43], positron emission tomography (PET) [44,45], and fMRI [46–49]. The rACC represents one of the main ‘hubs’ within the default network (DN), an intrinsically organized functional network that has been associated with a variety of self-referential processes, including introspective processing, remembering the past, and planning the future [50–53]. Dysregulation of the hypothalamus and hyperactivity of the rACC are both frequently observed in depression, but how these two regions interact with one another is poorly understood [22,33].

Our results extended previous findings and found that decreased MH-rACC FC during tVNS may reveal the antidepressant effect of tVNS treatment based on bottom-up processing. Specifically, continuous tVNS modulates the activity of the nucleus of the solitary tract (NTS), a series of nuclei that relay information to the hypothalamus and subgenual cortex in major depression [22]. Although both MH and LH are involved in the regulation of reward and mood and modulate anxiety-like behavior [18], they may belong to different neural circuits. For example, using the seeds applied in our study, Kullmann et al. suggested that MH and LH are tapped into different neural networks. Specifically, the MH network, which reflects major components of the reward system, is responsible for salience and learning and emotion, while LH is integrated into the dorsal striatum network which has been proposed as a translational network linking cognition and emotion or salience processing [30]. In this study, we demonstrated specific neural modulation pathways between the hypothalamus and ACC during tVNS treatment of MDD. Further studies are needed to validate our findings.

There are several limitations in this study. First, the treatment was only four weeks in duration. Thus, the results obtained only represent short-term to mid-term effects. Further studies are needed to evaluate the long-term effects of tVNS treatment. Second, we did not have detailed medical histories of these patients; thus we could not include these factors as covariates in the analyses. Third, the treatment effect of tVNS may have been influenced by the short washout period (i.e. the period of time when patients stop taking antidepressants or other psychiatric medications prior to intervention). Our experimental setup has minimized this potentially confounding factor by comparing real and sham treatment groups with an identical washout time. Fourth, all patients were recruited from participating hospitals through advertisements and flyers, and both real and sham groups were recruited using identical criteria. We believe this convenience sample method should not influence the validity of this study, but we cannot ensure that the sample selected in this study represents the population of MDD patients.
entire population. Future randomized studies in different populations are needed to further replicate our findings. Finally, this is not a randomized study. Being the first study to use only tVNS on patients suffering from mild and moderate depression, we thought it would be wise to first test the effectiveness of tVNS. We first completed the real tVNS cohort and then collected data for the sham tVNS cohort. Since the baseline characteristics were similar in the two cohorts of patients and the study was completed within 1 year, we do not expect the design to largely influence the validity of the study. Nevertheless, future studies with a randomized study design are needed.

Conclusion

In summary, we found that continuous tVNS, but not sham tVNS, significantly modulated the strength of MH–rACC FC, and the strength of this connection during treatment was significantly associated with tVNS treatment effects. Our findings provide a biomarker for the tVNS state and a better understanding of the neural mechanism underlying tVNS treatment in MDD patients.

Conflicts of interest

J.K has a disclosure to report (holding equity in a startup company (MNT) and pending patents to develop new neuromodulation devices), all other authors declare no conflict of interest.

Acknowledgement

The work is supported by Beijing Municipal Science & Technology Commission (Z161100002616003), the National Natural Science Foundation of China (81471389, 81303056, 81674072, 81774433). Jian Kong is supported by R01AT006364, R01AT008563, R01AT008707, P01AT006663 from NIH/NCRR.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.brs.2018.01.006.

References


